Trials / Terminated
TerminatedNCT05381909
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-24714 | administered orally |
| DRUG | Paclitaxel | administered intravenously |
| DRUG | Carboplatin | administered intravenously |
| DRUG | Docetaxel | administered intravenously |
Timeline
- Start date
- 2022-07-06
- Primary completion
- 2025-07-25
- Completion
- 2025-07-25
- First posted
- 2022-05-19
- Last updated
- 2026-02-20
Locations
34 sites across 5 countries: United States, Australia, China, New Zealand, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05381909. Inclusion in this directory is not an endorsement.